umicell has introduced LumiSystem to the US market, marking a significant advancement in real-time cancer detection during breast-conserving surgeries. This innovative system provides surgeons with immediate visualisation of cancerous tissue, improving the chances of complete tumour removal in a single procedure.
The LumiSystem integrates two key components: the FDA-approved Lumisight optical imaging agent and the Lumicell Direct Visualisation System (DVS). Together, they enable real-time detection of residual cancer within the surgical cavity, helping to address a longstanding challenge in breast cancer surgery.
Leggi il resto dell’articolo originale su Med-tech.world